Change From Baseline in Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) · Source last updated 2025-10-29
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, at approximately 58 months
What was measured
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The change from baseline at end of treatment is reported.
Analysis population: ITT Population included all participants who were randomized. All participants with PRO measurements at baseline and with data available at end of treatment were analyzed for this outcome measure.
Groups in this outcome
Azacitidine 75 mg/m^2
Participants were administered azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Participants were administered azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Reported measurements
Global Health Status/QoL Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
60.3
22.11
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
61.6
21.13
Not reported
Not reported
Not reported
Global Health Status/QoL Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
124
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-3.0
25.93
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-8.4
26.89
Not reported
Not reported
Not reported
Physical Functioning Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
69.4
22.63
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
75.7
20.38
Not reported
Not reported
Not reported
Physical Functioning Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
125
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-7.5
22.82
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-13.4
27.51
Not reported
Not reported
Not reported
Role Functioning Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
66.9
30.88
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
73.7
28.55
Not reported
Not reported
Not reported
Role Functioning Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
126
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-11.8
35.41
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-18.3
36.72
Not reported
Not reported
Not reported
Emotional Functioning Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
76.0
20.96
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
77.6
22.10
Not reported
Not reported
Not reported
Emotional Functioning Score: Change from Baselline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
124
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-2.5
23.80
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-5.9
22.41
Not reported
Not reported
Not reported
Cognitive Functioning Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
84.6
18.29
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
86.1
17.60
Not reported
Not reported
Not reported
Cognitive Functioning Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
125
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-7.2
22.65
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-10.4
24.38
Not reported
Not reported
Not reported
Social Functioning Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
208
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
79.3
25.37
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
78.8
25.82
Not reported
Not reported
Not reported
Social Functioning Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
122
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-13.7
33.89
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-16.5
34.78
Not reported
Not reported
Not reported
Fatigue Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
38.5
25.44
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
33.8
24.24
Not reported
Not reported
Not reported
Fatigue Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
126
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
6.6
26.41
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
12.3
31.22
Not reported
Not reported
Not reported
Nausea/Vomiting Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
4.6
11.39
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
4.7
10.96
Not reported
Not reported
Not reported
Nausea/Vomiting Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
125
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
2.4
19.08
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
1.9
15.00
Not reported
Not reported
Not reported
Pain Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
20.9
25.55
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
19.4
26.42
Not reported
Not reported
Not reported
Pain Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
125
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
5.8
30.36
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
6.8
33.34
Not reported
Not reported
Not reported
Dyspnoea Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
25.4
29.83
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
24.4
28.90
Not reported
Not reported
Not reported
Dyspnoea Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
124
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
5.9
28.95
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
5.9
29.46
Not reported
Not reported
Not reported
Insomnia Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
27.2
27.96
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
25.7
30.68
Not reported
Not reported
Not reported
Insomnia Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
145
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
124
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
3.2
34.32
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
4.6
34.09
Not reported
Not reported
Not reported
Appetite Loss Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
23.4
29.29
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
15.6
23.99
Not reported
Not reported
Not reported
Appetite Loss Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
125
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
4.6
38.68
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
16.0
34.03
Not reported
Not reported
Not reported
Constipation Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
14.7
24.78
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
13.8
22.47
Not reported
Not reported
Not reported
Constipation Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
125
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
5.5
29.56
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
5.1
28.42
Not reported
Not reported
Not reported
Diarrhoea Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
210
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
7.6
18.84
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
7.0
16.75
Not reported
Not reported
Not reported
Diarrhoea Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
124
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
3.0
22.80
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
1.9
27.65
Not reported
Not reported
Not reported
Financial Difficulties Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
208
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
14.2
25.37
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
18.4
26.76
Not reported
Not reported
Not reported
Financial Difficulties Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
146
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
122
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
5.9
27.03
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
7.4
30.46
Not reported
Not reported
Not reported
QLQ-C30 Summary Score: Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
211
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
208
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
77.9
14.90
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
80.5
15.08
Not reported
Not reported
Not reported
QLQ-C30 Summary Score: Change from Baseline
Analysis denominator · Participants
Group
Source count
Azacitidine 75 mg/m^2
145
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
120
Values in score on a scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Azacitidine 75 mg/m^2
-6.1
18.84
Not reported
Not reported
Not reported
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
-8.6
17.75
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
spread
22.11
value
60.3
group Id
OG001
spread
21.13
value
61.6
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
210
units
Participants
title
Global Health Status/QoL Score: Baseline
categories
measurements
group Id
OG000
spread
25.93
value
-3.0
group Id
OG001
spread
26.89
value
-8.4
denoms
counts
group Id
OG000
value
146
group Id
OG001
value
124
units
Participants
title
Global Health Status/QoL Score: Change from Baseline
categories
measurements
group Id
OG000
spread
22.63
value
69.4
group Id
OG001
spread
20.38
value
75.7
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
210
units
Participants
title
Physical Functioning Score: Baseline
categories
measurements
group Id
OG000
spread
22.82
value
-7.5
group Id
OG001
spread
27.51
value
-13.4
denoms
counts
group Id
OG000
value
146
group Id
OG001
value
125
units
Participants
title
Physical Functioning Score: Change from Baseline
categories
measurements
group Id
OG000
spread
30.88
value
66.9
group Id
OG001
spread
28.55
value
73.7
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
210
units
Participants
title
Role Functioning Score: Baseline
categories
measurements
group Id
OG000
spread
35.41
value
-11.8
group Id
OG001
spread
36.72
value
-18.3
denoms
counts
group Id
OG000
value
146
group Id
OG001
value
126
units
Participants
title
Role Functioning Score: Change from Baseline
categories
measurements
group Id
OG000
spread
20.96
value
76.0
group Id
OG001
spread
22.10
value
77.6
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
210
units
Participants
title
Emotional Functioning Score: Baseline
categories
measurements
group Id
OG000
spread
23.80
value
-2.5
group Id
OG001
spread
22.41
value
-5.9
denoms
counts
group Id
OG000
value
146
group Id
OG001
value
124
units
Participants
title
Emotional Functioning Score: Change from Baselline
categories
measurements
group Id
OG000
spread
18.29
value
84.6
group Id
OG001
spread
17.60
value
86.1
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
210
units
Participants
title
Cognitive Functioning Score: Baseline
categories
measurements
group Id
OG000
spread
22.65
value
-7.2
group Id
OG001
spread
24.38
value
-10.4
denoms
counts
group Id
OG000
value
146
group Id
OG001
value
125
units
Participants
title
Cognitive Functioning Score: Change from Baseline
categories
measurements
group Id
OG000
spread
25.37
value
79.3
group Id
OG001
spread
25.82
value
78.8
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
208
units
Participants
title
Social Functioning Score: Baseline
categories
measurements
group Id
OG000
spread
33.89
value
-13.7
group Id
OG001
spread
34.78
value
-16.5
denoms
counts
group Id
OG000
value
146
group Id
OG001
value
122
units
Participants
title
Social Functioning Score: Change from Baseline
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
210
units
Participants
description
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The change from baseline at end of treatment is reported.
dispersion Type
Standard Deviation
groups
description
Participants were administered azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.
id
OG000
title
Azacitidine 75 mg/m^2
description
Participants were administered azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.
id
OG001
title
Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
param Type
MEAN
population Description
ITT Population included all participants who were randomized. All participants with PRO measurements at baseline and with data available at end of treatment were analyzed for this outcome measure.
reporting Status
POSTED
time Frame
Baseline, at approximately 58 months
title
Change From Baseline in Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30
Triangle